Evidence map›Paper›PMID 42056360›Full record

ReviewInternational urology and nephrology2026

Blood pressure effects of SGLT2 inhibitors in kidney transplant recipients: a systematic review and meta-analysis.

Abdullah Ahmad, Muhammad Hasnain Mankani, Abdullah Al-Kahil, Mahrukh Khan, Mariam Ismail, Mary Bilancini, Sapana Verma, Muhammad Ahmad Nadeem, Ahmed Sayed Ahmed

Abstract readReview
PubMed Publisher
In one paragraph

Review in International urology and nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Abdullah Ahmad *Department of Medicine, Hamid Latif Teaching Hospital, Lahore, Pakistan.
Muhammad Hasnain Mankani *The Aga Khan University, Karachi, Pakistan.
Abdullah Al-KahilUniversity Hospitals Parma Medical Center, Parma, OH, USA.
Mahrukh KhanTouro College of Osteopathic Medicine, Harlem, USA.
Mariam IsmailTransplantation Center, Department of General Surgery. Digestive Disease Institute, Cleveland Clinic, 2049 E 100Th Street, Cleveland, OH, 44195, USA.
Mary BilanciniTransplantation Center, Department of General Surgery. Digestive Disease Institute, Cleveland Clinic, 2049 E 100Th Street, Cleveland, OH, 44195, USA.
Sapana VermaTransplantation Center, Department of General Surgery. Digestive Disease Institute, Cleveland Clinic, 2049 E 100Th Street, Cleveland, OH, 44195, USA.
Muhammad Ahmad NadeemTransplantation Center, Department of General Surgery. Digestive Disease Institute, Cleveland Clinic, 2049 E 100Th Street, Cleveland, OH, 44195, USA.
Ahmed Sayed AhmedTransplantation Center, Department of General Surgery. Digestive Disease Institute, Cleveland Clinic, 2049 E 100Th Street, Cleveland, OH, 44195, USA. sayedaa@ccf.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPost-transplant hypertension is common in kidney transplant recipients and contributes to cardiovascular risk and allograft dysfunction. Most available data come from studies where the primary indication for SGLT2 inhibitor use was post-transplant diabetes mellitus or cardiorenal protection, with blood pressure assessed as a secondary outcome.

objectivesTo systematically evaluate the impact of SGLT2 inhibitors on blood pressure, metabolic and renal outcomes, and safety in kidney transplant recipients.

methodsPubMed, Embase, and Scopus clinical trial registries were systematically searched from inception to October 20, 2025. Randomized controlled trials and observational studies were included. Primary outcomes were changes in systolic and diastolic blood pressure at 3, 6, and 12 months. Secondary outcomes included body weight, glycated hemoglobin (HbA1c), renal function, and adverse events.

resultsTwelve studies comprising 1,292 participants were included. In controlled difference-in-differences analyses (5 studies), SGLT2 inhibitors showed no significant blood pressure reductions versus control at any time point. Exploratory single-arm analyses suggested within-group systolic blood pressure reductions at 3 and 6 months; however, these estimates are at high risk of bias and cannot establish treatment effect.

conclusionExploratory single-arm analyses suggested modest short-term reductions in systolic blood pressure and suggested metabolic effects with an acceptable safety profile. However, controlled difference-in-differences analyses showed no significant blood pressure reductions versus control. Most available evidence derives from studies in which SGLT2 inhibitors were not initiated specifically for blood pressure control. Dedicated randomized controlled trials are required to determine their role in the management of post-transplant hypertension.

Indexed as

Blood pressureHypertensionKidney transplantationMeta-analysisPostoperative outcomeSGLT2 inhibitorsSystematic review

Identifiers

PMID42056360

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.